Good Medicine Begins in The Garden

Cannabis Research Information

INFLAMMATION – CANNABIS RESEARCH

OVERVIEW OF INFLAMMATION

WHILE INFLAMMATION IS AN ESSENTIAL RESPONSE BY THE BODY’S IMMUNE SYSTEM TO INJURY, BACTERIA AND VIRUSES, AT TIMES, THE INFLAMMATORY RESPONSE EFFECTIVELY REMOVES THE INFECTIOUS OR DAMAGING STIMULI SO THAT THE BODY CAN HEAL. HOWEVER, WHEN CALLED UPON UNNECESSARILY, IN THE CASE OF AUTOIMMUNE DISEASES, THE IMMUNE SYSTEM REACTS AS IF TISSUES ARE INFECTED OR ABNORMAL WHEN IN ACTUALITY THEY ARE NORMAL.  AS A RESULT, THE BODY CAUSES DAMAGE TO ITS OWN TISSUES.

Examples of diseases that are associated with inflammation include rheumatoid arthritis, a chronic inflammatory disease that causes joint destruction, deformity and loss of function, psoriatic arthritis, which causes joint pain, stiffness and swelling, as well as red patches on the skin, Crohn’s and other inflammatory bowel diseases where the digestive tract becomes inflamed, atherosclerosis, the inflammation of arterial walls that can limit or block blood flow and cause heart attacks and stroke, and some cancers.

Treatment of inflammatory diseases typically involves anti-inflammatory and pain medications and the modifying or avoidance of particular activities that stress the inflamed area. In certain cases, surgery is required.

FINDINGS: EFFECTS OF CANNABIS ON INFLAMMATION

Medical marijuana has been found to be effective at both reducing chronic inflammation and at curtailing the pain associated with inflammatory-related diseases, thanks to its cannabinoids, including tetrahydrocannabinol (THC). Cannabinoids have demonstrated success at reducing inflammation related to a variety of conditions. Studies have shown that THC is able to reduce the development of atherosclerosis, the chronic inflammatory disease and a major risk factor of heart attacks and strokes, and at reducing airway inflammation related to the flu virus

Inflammatory pain is a common symptom of a number of chronic inflammation diseases, such as sickle cell disease and cancer, but cannabis has proven helpful in pain management. The cannabinoids in cannabis act upon the cannabinoid receptors 1 and 2 (CB1, CB2), which are involved in the mediation of pain associated with inflammation (Clayton, Marshall, Bountra & O’Shaughnessy, 2002).

RECENT STUDIES ON CANNABIS’ EFFECT ON INFLAMMATION

THC decreased throat inflammation in mice with swollen air pathways from the flu virus.  Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence of presence of Delta9-tetrahydrocannabinol http://www.jleukbio.org/content/83/3/785.long

The administration of THC reduced the development of atherosclerosis, an inflammatory disease of the blood vessels that causes heart attacks and stroke. Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. https://www.sciencedirect.com/science/article/pii/S0090698098000689


References:

  1. Acharya, N., Penukonda, S., Shcheglova, T., Hagymasi, A.T., Basu, S., and Srivastava, P.K. (2017, March 27). Endocannabinoid system acts as a regulator of immune homeostasis in the gut. Proceedings of the National Academy of Sciences of the United States, 114(19), 5005-5010. Retrieved from https://www.pnas.org/content/114/19/5005.full
  2. Adhikary, S., Li, H., Heller, J., Skarica, M., Zhang, M., Ganea, D., and Tuma, R.F. (2011). Modulation of Inflammatory Responses by a Cannabinoid-2–Selective Agonist after Spinal Cord Injury. Journal of Neurotrauma 28 (12), 2417–2427. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235339/
  3. Buchweitz, JP., Karmaus, PW., Williams, KJ., Harkema, JR. and Kaminski, NE. (2008, March). Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence of presence of Delta9-tetrahydrocannabinol. Journal of Leukocyte Biology, 83(3), 785-96. Retrieved from http://www.jleukbio.org/content/83/3/785.long
  4. Clayton, N., Marshall, FH., Bountra, C., and O’Shaughnessy, CT. (2002, April). CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96(3), 253-60. Retrieved from https://journals.lww.com/pain/pages/articleviewer.aspx?year=2002&issue=04000&article=00005&type=abstract
  5. Craft, R.M., Kandasamy, R., and Davis, S.M. (2013, September). Sex differences in anti-allodynic, anti-hyperalgesic and anti-edema effects of Δ9-tetrahydrocannabinol in the rat., 154(9), 1709-17. Retrieved from https://journals.lww.com/pain/Citation/2013/09000/Sex_differences_in_anti_allodynic,.28.aspx
  6. Croxford, J.L., and Yamamura, T. (2005, September). Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?Journal of Neuroimmunology, 166(1-2), 3-18. Retrieved from http://www.jni-journal.com/article/S0165-5728(05)00160-8/fulltext
  7. De Laurentiis, A., Araujo, H.A., and Rettori, V. (2014). Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation. Current Pharmaceutical Design, 20(29), 4697-706. Retrieved from http://www.eurekaselect.com/120077/article
  8. De Petrocellis, L., Melck, D., Bisogno, T., and Di Marzo, V. (2000, November). Endocannabinoids and fatty acid amides in cancer inflammation and related disorders. Chemistry and Physics of Lipids, 108(1-2), 191-209. Retrieved from https://www.sciencedirect.com/science/article/pii/S0009308400001961
  9. Fimiani, C., Liberty, T., Aquirre, AJ., Amin, I., Ali, N. and Stefano, GB. (1999, January). Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. Prostaglandins & Other Lipid Mediators, 57(1), 23-34. Retrieved from http://www.sciencedirect.com/science/article/pii/S0090698098000689
  10. Fukuda, S., Kohsaka, H., Takayasu, A., Yokoyama, W., Miyabe, C., Miyabe, Y., Harigai, M., Miyasaka, N., and Nanki, T. (2014). Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC Musculoskeletal Disorders, 275. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243420
  11. Kinsey, S.G., Mahadevan, A., Zhao, B., Sun, H., Naidu, P.S., Razdan, R.K., Selley, D.E., Imad Damaj, M., and Lichtman, A.H. (2011). The CB cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60/(2-3), 244–251. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021987/
  12. Klein, T.W. (2005, May). Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology, 5, 400-411. Retrieved from https://www.nature.com/articles/nri1602.html
  13. Matthews, A.T., and Ross, M.K. (2015). Oxyradical Stress, Endocannabinoids, and Atherosclerosis. Toxics 3/(4), 481–498. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4686160/
  14. Michalski, C.W., Maier, M., Erkan, M., Sauliunaite, D., Bergmann, F., Pacher, P., Batkai, S., Giese, N.A., Giese, T., Friess, H., and Kleeff, J. (2008). Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253501/
  15. Panikashvili, D., Shein, N.A., Mechoulam, R., Trembovler, V, Kohen, R., Alexandrovich, A. and Shohami, E. (2006, May). The endocannabinoid 2-AG protects the blood–brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiology of Disease, 22(2), 257-264. Retrieved from https://www.sciencedirect.com/science/article/pii/S0969996105003074
  16. Parker, J., Atez, F., Rossetti, R.G., Skulas, A., Patel, R., and Zurier, R.B. (2008, May). Suppression of human macrophage interleukin-6 by a nonpsychoactive cannabinoid acid. Rheumatology International, 28(7), 631-5. Retrieved from https://link.springer.com/article/10.1007%2Fs00296-007-0489-0
  17. Wright, K.L., Duncan, M., and Sharkey, K.A. (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. British Journal of Pharmacology, 153(2), 263–270. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2219529/